World News: 12:00 GMT Friday 21st April 2017. [NewLink Genetics Corporation via Globe Newswire via SPi World News]
AMES, Iowa, April 21, 2017 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The complete text of the abstracts will be posted online at 5:00 p.m. ET on Wednesday, May 17.
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit .
Director of Investor Relations
Beth Kurth, VP
(617) 374-8800, ext. 106
Sharon Correia, VP
(617) 374-8800, ext. 105
Globe Newswire: 12:00 GMT Friday 21st April 2017
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.